Targeted protein degradation companies develop medicines that direct disease-associated proteins towards the cell’s natural disposal machinery. These technologies can remove proteins rather than simply blocking their activity, creating new approaches to previously difficult drug targets.
This category includes companies working on:
Browse 13 UK targeted protein degradation companies below.
Automated chiral chemistry platform for small molecule drug discovery
LCC Technologies is a drug discovery company providing biopharma partners with access to its platform, which combines a proprietary billion-scale virtual chiral library with AI-driven design and automated high-throughput synthesis. The platform delivers stereodefined, sp3-rich building blocks and drug-like compounds…
Specialty chemical building blocks and reagents for drug discovery research
Fluorochem is a UK manufacturer and supplier of specialty chemicals, reagents and biochemical building blocks, with a catalogue spanning several hundred thousand products used across chemistry, pharmaceuticals and medicinal chemistry research. The company's offering includes ADC linkers, PROTACs, bioconjugation tools…
AI platform engineering molecular glue drugs for undruggable targets
Ternary Therapeutics is a preclinical-stage biotechnology company developing an AI-driven platform for the rational design of molecular glue therapeutics. Molecular glues are small molecules that induce proximity between two proteins, enabling targeted degradation or modulation of disease-driving targets that lack…
Chemistry-led CRO and CDMO for pharmaceutical and diagnostics R&D
High Force Research is an independent chemistry CRO and CDMO providing synthetic chemistry, process development, and GMP manufacturing services to the pharmaceutical, biotech, and diagnostics industries. Services span route design, complex synthesis, scale-up, and analytical development through to regulatory-grade…
Integrated contract drug discovery from Cambridge and India
o2h is a contract research organisation operating an integrated drug discovery platform from Cambridge, UK, and Ahmedabad, India. Core services span medicinal chemistry, biology, DMPK, and non-GMP scale-up, supporting hit-to-lead optimisation through to IND-enabling studies. The company works across small molecule,…
Phenotypic screening platform for targeted protein degradation drug discovery
PhoreMost is a drug discovery company developing a phenotypic screening platform to identify and prosecute previously undruggable disease targets. The platform systematically unmasks cryptic binding sites across the human proteome and links them to therapeutic functions in a live-cell context, enabling the discovery…
Small molecule protein degraders targeting oncology and CNS disease
Kesmalea Therapeutics is a biotechnology company developing oral small molecule therapeutics that modulate protein homeostasis through targeted protein degradation and stabilisation. The company's platform is designed to convert the potency of protein degrader approaches into orally bioavailable, CNS-penetrant small…
Precision oncology drug discovery via targeted protein degradation
Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its…
Targeted protein degradation platform for neurodegenerative disease
TRIMTECH Therapeutics is a biotechnology company developing small-molecule degraders that selectively remove disease-causing protein aggregates while preserving the functional, non-aggregated forms of the same proteins. The platform is built on research into the E3 ubiquitin ligase TRIM21, conducted over nearly two…
Tunable covalent chemistry platform for neurodegenerative disease
Dunad Therapeutics is a drug discovery biotech developing small molecule therapies for neurodegenerative diseases including ALS, frontotemporal dementia, and Parkinson's disease. Its platform combines tunable covalent chemistry with targeted protein degradation, using monovalent small molecules that form durable bonds…
Next-generation targeted protein degradation therapeutics
Amphista Therapeutics is a Cambridge-based biopharmaceutical company developing next-generation targeted protein degradation medicines. Its proprietary platform generates bifunctional small molecule degraders that harness a broader range of the cell's protein-degrading machinery than existing approaches, enabling…
E3 ligase inhibitors stabilising tumour suppressor proteins
Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune…
Global biopharma focused on severe neurological and immunological diseases
UCB Pharma is the UK subsidiary of UCB S.A., a Belgian biopharmaceutical company focused on the discovery and development of treatments for severe neurological and immunological diseases. The UK operation is one of UCB's three global R&D hubs, with capabilities spanning antibody discovery, small molecule development,…